» Articles » PMID: 25935891

Quantitative Correlation Between Cardiac MIBG Uptake and Remaining Axons in the Cardiac Sympathetic Nerve in Lewy Body Disease

Overview
Date 2015 May 4
PMID 25935891
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Reduced cardiac meta-iodobenzylguanidine (MIBG) uptake and loss of cardiac sympathetic axons, as its possible anatomical substrate, were both recognised in Lewy body disease (LBD), while their direct correlation has so far remained speculative. Increasing availability of autopsy-confirmed cases of LBD prompted us to quantify residual cardiac sympathetic axons to establish their relationship to cardiac MIBG uptake.

Methods: We collected cardiac tissue samples from 23 patients with autopsy-confirmed LBD and two non-LBD control patients who underwent (123)I-MIBG cardiac scintigraphy in life. Samples of the left ventricular anterior wall were stained with anti-tyrosine hydroxylase (TH) and anti-neurofilament (NF) antibodies as markers of cardiac nerve axons. We quantified the immunolabelled areas and assessed their correlation to standardised heart to mediastinum (H/M) ratios of (123)I-MIBG cardiac scintigraphy.

Results: Cardiac MIBG uptake in the early and delayed phases was reduced in 90.9% and 95.7% of patients with LBD, respectively. The area of TH-immunoreactive axons correlated significantly with the H/M ratio in the early (p=0.036) as well as in the delayed (p=0.018) phases. The area of NF-immunoreactive axons also correlated with the H/M ratio in the early (p=0.003) as well as in the delayed (p=0.001) phases.

Conclusions: Tight quantitative correlation between cardiac (123)I-MIBG uptake and corresponding loss of sympathetic axons in LBD, as established for the first time by this study, provides a scientific basis to confirm the reliability of MIBG cardiac scintigraphy as a powerful clinical tool to detect loss of these axons as a biomarker for the presence of Lewy body disease.

Citing Articles

Diagnostic Efficacy of Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies.

Hagen J, Scheifele M, Zacherl M, Katzdobler S, Bernhardt A, Brendel M Diagnostics (Basel). 2025; 15(1.

PMID: 39795552 PMC: 11720076. DOI: 10.3390/diagnostics15010024.


Gastric emptying time and its correlation with cardiac MIBG in body-first and brain-first subtype Parkinson's disease.

Kim M, Park D, Shin I, An Y, Yoon J J Neurol. 2024; 272(1):28.

PMID: 39665845 DOI: 10.1007/s00415-024-12783-6.


Comparison of MIBG uptake in the major salivary glands between Lewy body disease and progressive supranuclear palsy.

Ebina J, Mizumura S, Shibukawa M, Morioka H, Nagasawa J, Yanagihashi M Clin Park Relat Disord. 2024; 11:100287.

PMID: 39659394 PMC: 11629250. DOI: 10.1016/j.prdoa.2024.100287.


The Clinical Role of Heart Rate Variability Assessment in Cognitively Impaired Patients and Its Applicability in Community Care Settings: A Systematic Review of the Literature.

Attreed A, Morand L, Pond D, Sturmberg J Cureus. 2024; 16(6):e61703.

PMID: 38975380 PMC: 11226213. DOI: 10.7759/cureus.61703.


Autonomic dysfunction in dementia with Lewy bodies: Focusing on cardiovascular and respiratory dysfunction.

Mizukami K PCN Rep. 2024; 2(3):e129.

PMID: 38867816 PMC: 11114397. DOI: 10.1002/pcn5.129.